Qinlock Dosage
Generic name: Ripretinib
50mg
Dosage form: tablet
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Nov 4, 2024.
Recommended Dosage
The recommended dosage of QINLOCK is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.
Instruct patients to swallow tablets whole.
Advise patients to take QINLOCK at the same time each day.
Advise patients to take a missed dose if less than 8 hours have passed since the missed scheduled dose.
Advise patients not to take an additional dose if vomiting occurs after taking QINLOCK and to continue with their next scheduled dose.
Dosage Modifications for Adverse Reactions
The recommended dose reduction for adverse reactions is:
- QINLOCK 100 mg orally once daily.
Permanently discontinue QINLOCK in patients who are unable to tolerate 100 mg orally once daily.
The recommended dosage modifications of QINLOCK for adverse reactions are provided in Table 1.
Adverse Reaction | Severitya | QINLOCK Dosage Modifications |
---|---|---|
a Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03). |
||
Palmar-Plantar Erythrodysesthesia Syndrome (PPES) | Grade 2 |
|
Grade 3 |
|
|
Hypertension | Grade 3 |
|
Grade 4 |
Permanently discontinue QINLOCK. | |
Left Ventricular Systolic Dysfunction | Grade 3 or 4 | Permanently discontinue QINLOCK. |
Arthralgia or Myalgia | Grade 2 |
|
Grade 3 |
|
|
Other Adverse Reactions | Grade 3 or 4 |
|
Dose Modifications for Moderate CYP3A Inducers
Avoid concomitant use of moderate CYP3A inducers during QINLOCK treatment.
If a moderate CYP3A inducer cannot be avoided, increase the QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period. Monitor for clinical response and tolerability. If the concomitant moderate CYP3A inducer is discontinued, resume QINLOCK dosage back to 150 mg once daily 14 days after the discontinuation of the moderate CYP3A inducer.
For patients concomitantly using a moderate CYP3A inducer with QINLOCK (taking QINLOCK twice daily) who missed a dose:
- If less than 4 hours have passed since the missed scheduled dose, advise the patient to take the missed dose as soon as possible and then take the next dose at the regularly scheduled time.
- If more than 4 hours have passed since the missed scheduled dose, advise the patient to skip the missed dose and then take the next dose at the regularly scheduled time..
More about Qinlock (ripretinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Stivarga
Stivarga (regorafenib) is used to treat metastatic colorectal cancer, gastrointestinal stromal ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Sutent
Sutent is a cancer medicine that is used to treat certain types of advanced or progressive tumors ...
Imkeldi
Imkeldi is used to treat specific types of leukemia (blood cancer), bone marrow disorders ...
Avapritinib
Avapritinib systemic is used for gastrointestinal stromal tumor, systemic mastocytosis
Sunitinib
Sunitinib systemic is used for gastrointestinal stromal tumor, pancreatic cancer, renal cell carcinoma
Regorafenib
Regorafenib systemic is used for colorectal cancer, gastrointestinal stromal tumor, hepatocellular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.